Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-26 @ 12:45 AM
Study NCT ID:
NCT01688960
Status:
COMPLETED
Last Update Posted:
2015-03-17
First Post:
2012-09-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-10
Start Date Type:
None
Primary Completion Date:
2014-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-11
Completion Date Type:
ACTUAL
First Submit Date:
2012-09-17
First Submit QC Date:
None
Study First Post Date:
2012-09-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-03-16
Last Update Post Date:
2015-03-17
Last Update Post Date Type:
ESTIMATED